GlassScriptPhysician profile
Antonio V Aragon
NPI 1992774590
$4,544.48
in general payments reported to CMS, 2019-2025
9 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $530 · 2021: $1,000 · 2022: $1,713 · 2023: $124 · 2024: $183 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $3,468.02 | 2019-2022 | |
| Alcon Vision LLC | $373.20 | 2019-2025 | Constellation, Unity |
| Genentech USA, INC. | $357.43 | 2019-2025 | Vabysmo |
| Astellas Pharma US INC | $178.18 | 2024-2025 | Izervay |
| Genentech, INC. | $72.83 | 2019 | |
| Abbvie INC. | $42.90 | 2022-2023 | Ozurdex |
| Coherus Oncology, INC. | $18.56 | 2023 | |
| Harrow Eye, LLC | $17.71 | 2024 | Triesence, Iheezo |
| Rxsight INC | $15.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$76,517.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Aragon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.